IND Swift Laboratories Ltd
NSE:INDSWFTLAB
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
IND Swift Laboratories Ltd
NSE:INDSWFTLAB
|
9.7B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
978.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
571.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.8B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
226.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.9B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.8B USD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
IND Swift Laboratories Ltd
Glance View
Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh. The company went IPO on 2002-03-15. The firm operates through the bulk drugs and pharmaceuticals segment. Its business includes Active Pharmaceutical Ingredients (APIs), Advanced Intermediates, and Contract Research and Manufacturing Services (CRAMS). The firm has a product portfolio of approximately 12 therapeutic segments. The company is manufacturing APIs of complex therapies namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Multidisciplinary skills Synthetic Medicinal Chemistry Custom Synthesis Process R&D cGMP Manufacturing Analytical Development Regulatory Support Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. The Company’s products and services include API products, custom chemicals, and impurities. The firm manufacturing facilities are at Derabassi and Jammu Kashmir.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for IND Swift Laboratories Ltd is 32.3%, which is above its 3-year median of 30.4%.
Over the last 3 years, IND Swift Laboratories Ltd’s Net Margin has increased from 0% to 32.3%. During this period, it reached a low of 0% on Sep 30, 2022 and a high of 79.2% on Dec 31, 2024.
